Literature DB >> 34001722

Effect of Levosimendan on Ventricular Systolic and Diastolic Functions in Heart Failure Patients: A Meta-Analysis of Randomized Controlled Trials.

Yu-Xiang Long1, Di-Yu Cui, Xue Kuang, Shuang Hu, Yue Hu, Zeng-Zhang Liu.   

Abstract

ABSTRACT: Levosimendan, a calcium sensitizer, exerts inotropic action through improving left ventricular ejection fraction. We noticed that only few clinical studies are published in which the effects of levosimendan on cardiac function are studied by echocardiography. When screening the literature (PubMed, Embase, and CENTRAL, from inception to August 2020), we found 29 randomized controlled trials on levosimendan containing echocardiographic data. We included those studies, describing a total of 574 heart failure patients, in our meta-analysis and extracted 14 ultrasonic parameters, pooling the effect estimates using a random-effect model. Our analysis of the diastolic parameters of the left ventricle shows that levosimendan reduce the early/late transmitral diastolic peak flow velocity ratio [standardized mean difference (SMD) -0.45 to 95% confidence interval (CI) (-0.87 to -0.03), P = 0.037] and E/e' (e': mitral annulus peak early diastolic wave velocity using tissue-doppler imaging) [SMD -0.59, 95% CI (-0.8 to -0.39), P < 0.001]. As it regards the systolic parameters of the right ventricle, levosimendan increased tricuspid annular plane systolic excursion [SMD 0.62, 95% CI (0.28 to 0.95), P < 0.001] and tricuspid annular peak systolic velocity [SMD 0.75, 95% CI (0.35 to 1.16), P < 0.001], and reduced systolic pulmonary artery pressure [SMD -1.02, 95% CI (-1.32, -0.73), P < 0.001]. As it regards the diastolic parameters of the right ventricle, levosimendan was associated with the decrease of Aa (peak late diastolic tricuspid annular velocity using tissue-doppler imaging) [SMD -0.38, 95% CI (-0.76 to 0), P = 0.047] and increase of Ea (peak early diastolic tricuspid annular velocity using tissue-doppler imaging) [SMD 1.03, 95% CI (0.63 to 1.42), P < 0.001] and Ea/Aa [SMD 0.86, 95% CI (0.18 to 1.54), P = 0.013]. We show that levosimendan is associated with an amelioration in the diastolic and systolic functions of both ventricles in heart failure patients.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34001722     DOI: 10.1097/FJC.0000000000001010

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  2 in total

1.  Levosimendan as a "Bridge to Optimization" in Patients with Advanced Heart Failure with Reduced Ejection-A Single-Center Study.

Authors:  Daniele Masarone; Michelle M Kittleson; Maria L Martucci; Fabio Valente; Rita Gravino; Marina Verrengia; Ernesto Ammendola; Carla Contaldi; Vito Di Palma; Angelo Caiazzo; Andrea Petraio; Piero Pollesello; Giuseppe Pacileo
Journal:  J Clin Med       Date:  2022-07-21       Impact factor: 4.964

2.  Levosimendan Administration May Provide More Benefit for Survival in Patients with Non-Ischemic Cardiomyopathy Experiencing Acute Decompensated Heart Failure.

Authors:  Wei-Chieh Lee; Po-Jui Wu; Hsiu-Yu Fang; Yen-Nan Fang; Huang-Chung Chen; Meng-Shen Tong; Pei-Hsun Sung; Chieh-Ho Lee; Wen-Jung Chung
Journal:  J Clin Med       Date:  2022-07-10       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.